Shanghai Mengchao Cancer Hospital
A research-oriented cancer hospital affiliated with Shanghai University and associated with Shanghai Cell Therapy Group โ offering multidisciplinary oncology, interventional procedures, precision radiotherapy, and investigational CAR-T studies.
About Shanghai Mengchao Cancer Hospital
Shanghai Mengchao Cancer Hospital โ formally Shanghai University Affiliated Mengchao Cancer Hospital โ is a research-oriented cancer facility in Jiading District, Shanghai, that began trial operations in May 2020 and was formally unveiled in December 2020. The hospital is named in honour of Professor Wu Mengchao, a prominent Chinese hepatobiliary surgeon, and is affiliated with Shanghai University School of Medicine. It is associated with Shanghai Cell Therapy Group, which is clinically relevant for patients interested in advanced immunotherapy and investigational cell-therapy pathways.
The hospital is planned with 410 beds and more than 40,000 square metres of space, and provides multidisciplinary cancer care through departments including medical oncology, surgical oncology, thoracic tumour surgery, biological treatment, radiotherapy, comprehensive interventional oncology, gastroenterology, urology, gynaecology, imaging, and nuclear medicine. Its radiotherapy centre is equipped with a Varian VitalBeam system for precision radiation treatment.
ClinicalTrials.gov records list investigational CAR-T studies associated with Shanghai Mengchao Cancer Hospital โ including mesothelin-targeted CAR-T, CD19/CD22/BCMA approaches, and CD19/CD22 bispecific studies. These are investigational pathways, not standard treatment. Eligibility, recruitment status, and international-patient access must be confirmed protocol-by-protocol before any patient is directed to travel.
CancerFax helps patients explore whether Shanghai Mengchao Cancer Hospital is relevant for their case โ by reviewing reports, identifying the appropriate department or clinical trial, coordinating preliminary hospital review, and clarifying international-patient support arrangements before travel is planned.
| Hospital at a Glance | |
|---|---|
| Country | China |
| City | Jiading District, Shanghai |
| Opened | Trial operations May 2020; formally opened December 2020 |
| Hospital Type | Research-oriented cancer hospital (tertiary-specialty hospital standards) |
| Affiliation | Shanghai University School of Medicine; associated with Shanghai Cell Therapy Group |
| Beds | 410 planned beds |
| Hospital Space | Over 40,000 square metres |
| Research Focus | Biological treatment, immunotherapy, CAR-T clinical trials, interventional oncology, precision radiotherapy |
Why Patients Choose This Hospital
Cancer Specialties and Clinical Departments
Advanced Treatment Capabilities
Our Medical Specialists
Shanghai Mengchao Cancer Hospital's clinical departments are led by named senior physicians including Prof. Xu Qing (Director, Medical Oncology and Biological Treatment Centre), Dr. Lou Jinxing (Director, Biological Treatment Centre), Dr. Ma Yougang (Director, Surgical Oncology), Prof. Zhang Yongjie (Pancreatic and biliary surgery), Dr. Li Yingping (Director, Thoracic Tumour Surgery), and Dr. Jiang Ping (Director, Radiotherapy Centre).
Doctor availability, appointment schedules, and suitability for a specific international patient case should be reconfirmed before publication and before arranging consultation. CancerFax coordinates case submission and physician routing.
Patients seeking specific physician consultations or second opinions may request a review through the CancerFax coordination process before confirming travel or admission.
World-Class Infrastructure
- Biological Treatment Centre with tumour immunotherapy and clinical-translation focus
- Investigational mesothelin-targeted CAR-T (NCT06248697, NCT06249256)
- CD19/CD22/BCMA CAR-T dose-escalation study for r/r myeloma (NCT06732232)
- CD19/CD22 bispecific CAR-T investigational study (NCT06446128, NCT07174843)
- Varian VitalBeam precision radiation therapy system
- GE large-aperture CT simulation scanner
- PET-CT (Discovery 710), 3.0T MRI, 320-row CT, DSA, and mammography
- Nuclear medicine with PET-CT, MRI, and ultrasound imaging support
- Hepatobiliary, pancreatic, and gastrointestinal surgical oncology
- Thoracic tumour surgery โ lung, esophageal, mediastinal, and chest-wall tumours
- Microwave ablation and vascular embolisation for unresectable lesions
- Iodine-125 seed implantation for local tumour control
- Chemotherapy, targeted therapy, immunotherapy, and endocrine therapy
- Multidisciplinary tumour treatment planning and personalised therapy pathways
- Supportive and palliative care integration within oncology
- Gastroenterology, endoscopy, urology, and gynaecology cancer pathways
Services for International Patients
What to Prepare Before Traveling
- arrow_rightFor clinical trial enquiries: prepare diagnosis reports, prior treatment history, tumour markers, organ function tests, and performance status โ these are minimum requirements for CAR-T trial eligibility pre-screening
- arrow_rightFor standard treatment: prepare pathology, imaging with DICOM files, treatment history, blood tests, and molecular reports
- arrow_rightConfirm international patient support, interpreter availability, and cost estimates with the hospital before booking travel โ these are not published on the hospital website
A dedicated international patient department is not clearly described on the hospital's public website. CancerFax submits reports and requests confirmation of acceptance, interpreter requirements, costs, and travel documentation before patients travel.
Patient Amenities & Facilities
Shanghai Mengchao Cancer Hospital is in Jiading District, approximately 35 km from Hongqiao Airport. CancerFax can help with accommodation and transport planning for international patients and accompanying family members.
How to Reach This Hospital
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Patient Questions Answered
CancerFax begins by reviewing your medical reports โ diagnosis, pathology, imaging, treatment history, tumour markers, and organ function โ to assess whether Shanghai Mengchao Cancer Hospital is relevant for your case, either for standard cancer treatment or for clinical-trial screening.
For CAR-T trial enquiries, we check your reports against the registered trial eligibility criteria (diagnosis, prior treatment lines, performance status, organ function) and coordinate submission to the trial team for pre-screening. For standard treatment, we prepare a case summary and submit to the relevant clinical department. Once the hospital provides guidance, CancerFax helps with interpreter arrangements, travel planning to Jiading District, and post-treatment continuity with your local oncologist.
ClinicalTrials.gov lists investigational CAR-T studies associated with Shanghai Mengchao Cancer Hospital, including mesothelin-targeted CAR-T for solid tumours and CD19/CD22/BCMA approaches for myeloma and B-cell cancers. These are investigational studies โ not routine treatments. Recruitment status, eligibility criteria, and international-patient access must be confirmed for each specific trial before any patient travels. CancerFax coordinates this pre-screening process.
Yes. The surgical oncology department describes treatment pathways for liver cancer, bile-duct cancer, pancreatic cancer, gastric cancer, colorectal cancer, and gastrointestinal stromal tumours. The interventional department provides complementary minimally invasive procedures including microwave ablation and embolisation for unresectable or recurrent cases.
Yes. The radiotherapy centre uses a Varian VitalBeam precision radiation system and a GE large-aperture simulation scanner. Precision radiation treatment is described as the department's core clinical focus. The appropriate technique and schedule depend on the tumour location, prior radiotherapy history, and treatment objectives โ assessed by the treating radiation oncologist.
The hospital provides an online consultation route through its WeChat channel, but a dedicated international patient department is not clearly described on the public website. CancerFax submits reports on behalf of international patients, requests confirmation of acceptance, clarifies interpreter and cost arrangements, and coordinates practical logistics before travel is planned.
Send Your Medical Reports to Shanghai Mengchao Cancer Hospital via CancerFax
Shanghai Mengchao Cancer Hospital offers multidisciplinary cancer surgery, precision radiotherapy, interventional oncology, immunotherapy, and investigational CAR-T trials. Share your reports with CancerFax for a structured case review.